PARIS (Reuters) – French healthcare giant Sanofi (NASDAQ:) has invested 50 million euros ($59 million) into Jeito Capital, an investment firm dedicated to biotech and biopharma, in a deal which Sanofi said would support French and European healthcare innovation.
“We are pleased to collaborate with Jeito Capital and its international team of pharma and biotech experts who are renowned for creating value through innovation,” said Sanofi Chief Executive Officer Paul Hudson (NYSE:) in a statement on Friday.
“This investment provides Sanofi with access to the very best in French and European healthcare innovation and reinforces our commitment to investing in our medium and long-term development pipeline,” said Hudson.
($1 = 0.8470 euros)
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.